The present invention provides methods and compositions for protein delivery. The invention features virus like particles, methods of making virus like particles and methods of using virus like particles to deliver proteins to a cell, to provide protein therapy and to treat diseases or disorders. The invention also features methods of targeting a protein to a cell, methods of protein therapy and methods of treating diseases or disorders using a TUS protein, a NLS or NES identified from full length TUS.

The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling molecule capable of binding and displaying antibodies or other Fc-containing targeting moiety fusions and conjugates.

A pneumococcal vaccine comprising a fusion protein at least comprising a full-length family 1 pneumococcal surface protein A (PspA) or a fragment thereof, and a full-length family 2 PspA or a fragment thereof, in particular any one of the following fusion proteins (1) to (3): (1) a fusion protein at least comprising a family 1, clade 2 PspA and a family 2, clade 3 PspA, (2) a fusion protein at least comprising a family 1, clade 2 PspA and a family 2, clade 4 PspA, and (3) a fusion protein at least comprising a family 1, clade 2 PspA and a family 2, clade 5 PspA,
is useful as a pneumococcal vaccine comprising a single protein antigen that has broadly cross-reactive immunogenicity and can induce immune response against a wide range of pneumococcal clinical isolates.

The present invention provides a fusion polypeptide comprising a biotin ligase enzyme fused to an immunoglobulin-binding bacterial protein, preferably wherein the immunoglobulin-binding bacterial protein is selected from Protein A, Protein G, Protein A/G and Protein L. The fusion polypeptide is preferably provided in combination with an antibody to which the immunoglobulin-binding bacterial protein can bind, and which combination is used for targeted proximity biotinylation.

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.

Fusion proteins comprising a protein expression enhancing polypeptide linked to a target protein binding domain and nucleic acid molecules encoding such fusion proteins are described for use in enhancing expression and/or location of a targeted protein of interest, for restoring lost functions in cells, and for treating disease. Additional fusion proteins comprising a target protein of interest modified with a fusion partner comprising a protein expression enhancing polypeptide are also disclosed.

The invention relates to genetically encoded fusion proteins comprised of a capture component that binds a target with high affinity and a peptide polymer, such as elastin-like polypeptides, that display phase behavior and can be used for purification. The invention further relates to methods for optimizing capture fusion proteins for individual biologic targets such that phase separation occurs under desirable conditions, such as at room temperature, lower concentrations of salt, and/or at suitable pH ranges and optimized capture domains and polypeptides with phase behavior that have been identified by the optimization methods.

A conjugate comprising a P. falciparum erythrocyte membrane protein 1 (PfEMP1) CIDR.sup.1.4 domain fused to a therapeutic agent.

This disclosure is directed to a targeted delivery vehicle that can deliver a cargo to a cell of interest. The targeted delivery vehicle has a fusogen and a targeting domain which are embedded in a lipid bilayer membrane that forms a vesicle, and a cargo within the vesicle. The disclosure is also directed to methods for targeted delivery of cargo using the targeted delivery vehicle described herein.

Polypeptides are disclosed comprising an (Fc) binding domain, a helical polypeptide monomer, and an oligomer domain, polymers thereof, and uses thereof.